Product Description
MABA for chronic obstructive pulmonary disease (Sourced from: https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology.html)
Mechanisms of Action: MR Antagonist, ADRB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease
Phase 1: Chronic Obstructive Pulmonary Disease|Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03159442 |
D6640C00005 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2017-10-13 |
2019-03-21 |
Treatments |
|
NCT02814656 |
D6640C00003 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2016-11-28 |
2019-03-20 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
NCT02573155 |
D6640C00001 | P1 |
Completed |
Asthma|Chronic Obstructive Pulmonary Disease |
2016-08-01 |
2019-03-20 |
||
NCT03645434 |
D6640C00006 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2019-08-07 |
41% |
2019-09-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2018-001722-25 |
2018-001722-25 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2019-08-07 |
2022-03-13 |
Treatments |
|
2016-002863-32 |
2016-002863-32 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2017-08-18 |
2022-03-13 |
Treatments |
|
NCT02971293 |
D6640C00004 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2017-08-18 |
2019-03-21 |
Treatments |